Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma

Technology appraisal guidance
Reference number: TA137
Published: 27 February 2008

Appendix B: proposal paper presented to NICE's Guidance Executive

Appendix B: proposal paper presented to NICE's Guidance Executive

Appendix B: proposal paper presented to NICE's Guidance Executive
17 January 2011
(113.51 Kb 33 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 17 January 2011